Search
Fennel
go.drugbank.com/drugs/DB15615ApprovedCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2E1 InhibitorsUlotaront
go.drugbank.com/drugs/DB15665InvestigationalUnlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesFenchone
go.drugbank.com/drugs/DB15918InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesHomochlorcyclizine
go.drugbank.com/drugs/DB15979InvestigationalCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsGarlic oil
go.drugbank.com/drugs/DB15989InvestigationalCategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsFinerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544] So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. … [A236519,L34739] Patients with kidney disease, would originally be given [spironolactone] or [eplerenone] to antagonize the mineraclocorticoid receptor.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesSotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigationalSotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLefamulin
go.drugbank.com/drugs/DB12825ApprovedLefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is av...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesQuizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalQuizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. A...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTrofosfamide
go.drugbank.com/drugs/DB12902InvestigationalTrofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates